{"hands_on_practices": [{"introduction": "The activation of the lectin pathway is not a simple on/off switch; it is highly sensitive to the density and arrangement of carbohydrate ligands on a pathogen's surface. This exercise challenges you to connect the molecular concept of binding affinity to the critical requirement for receptor clustering, which drives MASP-2 autoactivation [@problem_id:2898679]. By calculating how a mutation affecting Ficolin-3's binding strength alters downstream C4 deposition, you will develop a quantitative intuition for how the immune system discriminates between low- and high-density displays of non-self patterns.", "problem": "A recombinant human ficolin-3 preparation is used to reconstitute lectin pathway initiation on a surface uniformly coated with N-acetylglucosamine (GlcNAc). Ficolin-3 is an oligomeric pattern-recognition molecule whose fibrinogen-related domain (FReD) binds acetylated sugars and recruits mannan-binding lectin-associated serine protease-2 (MASP-2), which upon activation cleaves complement component C4 to generate surface-bound C4b. Consider two otherwise identical reconstitutions that differ only in the FReD: wild-type versus a point mutant that selectively reduces GlcNAc binding. Each reaction contains recombinant ficolin-3 (either wild-type or mutant) pre-complexed with MASP-2 at the same molar ratio, purified human C4 and C2 at saturating concentrations, and buffer with physiologic ionic strength and calcium. No other collectins, ficolins, or pentraxins are present.\n\nSurface ligand density is sufficiently high that the effective dissociation constant for multivalent binding to the surface is approximately $K_{D,\\mathrm{eff}}^{\\mathrm{WT}} = 10$ nM for wild-type and $K_{D,\\mathrm{eff}}^{\\mathrm{mut}} = 100$ nM for the mutant. The bulk concentration of ficolin-3 in both reactions is $[P] = 50$ nM. MASP-2 autoactivation requires juxtaposition of at least two occupied pattern-recognition complexes on the surface, and C4b deposition occurs where activated MASP-2 cleaves C4, exposing a thioester that reacts with nearby hydroxyl groups on the surface.\n\nWhich prediction best describes how the mutation will alter downstream C4 deposition on the GlcNAc-rich surface under these conditions?\n\nA. The mutant will show an approximately $6$- to $7$-fold reduction in the initial rate of surface C4b deposition with sparser and smaller C4b microclusters, without a compensatory increase in fluid-phase C4 consumption.\n\nB. There will be no significant change in surface C4b deposition because MASP-1 fully substitutes for MASP-2 in C4 cleavage even when ficolin-3 binding is reduced.\n\nC. Surface C4b deposition will be largely unchanged, but total C4 consumption will increase due to MASP-2 activation in solution after dissociation from the surface, causing more fluid-phase C4 cleavage.\n\nD. C4b deposition will be completely abrogated because any reduction in GlcNAc binding eliminates MASP-2 activation on the surface.", "solution": "The goal is to reason from first principles about how decreasing N-acetylglucosamine (GlcNAc) binding by the fibrinogen-related domain (FReD) of ficolin-3 influences downstream complement C4b deposition via the lectin pathway.\n\nFoundational facts and definitions:\n\n- In the lectin pathway, pattern-recognition proteins such as mannose-binding lectin (MBL) and ficolins bind carbohydrate ligands on microbial surfaces and recruit mannan-binding lectin-associated serine proteases (MASPs). Mannan-binding lectin-associated serine protease-2 (MASP-2) is the primary enzyme that cleaves complement component C4 into C4a and C4b; C4b exposes a thioester that covalently attaches to nearby hydroxyl or amine groups on the surface.\n\n- Binding equilibria for receptor–ligand interactions can be described by the law of mass action. For independent surface sites with an effective dissociation constant $K_{D,\\mathrm{eff}}$, the fractional occupancy $f$ at bulk concentration $[P]$ is $f = \\dfrac{[P]}{[P] + K_{D,\\mathrm{eff}}}$.\n\n- MASP-2 autoactivation in the lectin pathway is strongly enhanced by clustering of pattern-recognition complexes on a surface; juxtaposition of at least two occupied complexes supports trans-activation and efficient cleavage of C4. On a homogeneous lattice with random independent binding, the probability that two neighboring sites are simultaneously occupied scales approximately with the square of the single-site occupancy, i.e., $\\propto f^{2}$.\n\n- Under saturating C4 and C2, the initial rate of C4b deposition on the surface will be proportional to the frequency of MASP-2 trans-activation events and therefore to the likelihood of adjacent occupied complexes. Thus, an appropriate phenomenological model for the initial rate $r$ is $r \\propto f^{2}$, all else equal.\n\nApply these principles to the provided parameters:\n\n- For wild-type with $K_{D,\\mathrm{eff}}^{\\mathrm{WT}} = 10$ nM at $[P] = 50$ nM, the fractional occupancy is\n$$\nf_{\\mathrm{WT}} = \\frac{50}{50 + 10} = \\frac{50}{60} \\approx 0.83.\n$$\n\n- For the mutant with $K_{D,\\mathrm{eff}}^{\\mathrm{mut}} = 100$ nM at $[P] = 50$ nM, the fractional occupancy is\n$$\nf_{\\mathrm{mut}} = \\frac{50}{50 + 100} = \\frac{50}{150} \\approx 0.33.\n$$\n\n- The relative probability of having adjacent occupied complexes (and hence the relative initial rate of C4b deposition) scales as the square of the occupancy. Compute the ratio:\n$$\n\\frac{r_{\\mathrm{mut}}}{r_{\\mathrm{WT}}} \\approx \\left(\\frac{f_{\\mathrm{mut}}}{f_{\\mathrm{WT}}}\\right)^{2} \\approx \\left(\\frac{0.33}{0.83}\\right)^{2} \\approx \\left(0.40\\right)^{2} \\approx 0.16.\n$$\nThis predicts roughly a $6$- to $7$-fold reduction in initial C4b deposition rate for the mutant compared to wild-type.\n\n- Spatial patterning: Lower occupancy decreases the size and density of clusters of active MASP-2 and therefore yields sparser and smaller C4b microclusters on the surface.\n\n- Fluid-phase consumption: MASP-2 activation is driven by surface clustering. When binding is weakened, both occupancy and clustering decrease, lowering the probability of MASP-2 autoactivation. This reduces, rather than increases, any potential fluid-phase C4 cleavage. Therefore, a compensatory rise in fluid-phase C4 consumption is not expected under the specified conditions.\n\nOption-by-option analysis:\n\nA. States an approximately $6$- to $7$-fold reduction in initial surface C4b deposition rate with sparser C4b microclusters and no compensatory increase in fluid-phase consumption. This matches the quantitative estimate $r_{\\mathrm{mut}}/r_{\\mathrm{WT}} \\approx 0.16$ and the mechanistic expectations about clustering and MASP-2 activation. Correct.\n\nB. Claims no change due to MASP-1 substituting for MASP-2 even when binding is reduced. While mannan-binding lectin-associated serine protease-1 (MASP-1) can cleave C2 and can contribute to MASP-2 activation, MASP-2 is the principal C4 convertase in the lectin pathway. The scenario specifies that MASP-2 is present and that binding is reduced; MASP-1 cannot fully compensate for reduced clustering-driven MASP-2 activation, and certainly not to the point of “no change.” Incorrect.\n\nC. Proposes unchanged surface deposition with increased fluid-phase C4 consumption due to MASP-2 activation in solution after dissociation. Reduced binding diminishes clustering and MASP-2 autoactivation, making increased fluid-phase activation unlikely. Moreover, the predominant productive C4 cleavage occurs at the surface where complexes reside; weakening surface binding does not preserve surface deposition while increasing fluid-phase waste. Incorrect.\n\nD. Asserts complete loss of C4 deposition. The mutant still exhibits finite occupancy ($f_{\\mathrm{mut}} \\approx 0.33$), permitting some clustering and MASP-2 activation; the predicted outcome is a reduction, not total abrogation. Incorrect.\n\nTherefore, the best prediction is option A.", "answer": "$$\\boxed{A}$$", "id": "2898679"}, {"introduction": "Once activated, the MBL-MASP complex functions as a potent enzymatic machine. This practice moves from the 'if' of activation to the 'how fast' by applying classical Michaelis-Menten kinetics to the cleavage of complement C4 by MASP-2 [@problem_id:2898645]. The core challenge lies in determining the true concentration of catalytically active enzyme from a series of experimentally plausible efficiency factors, a crucial skill for interpreting in vitro biochemical data.", "problem": "In the lectin complement pathway, Mannose-Binding Lectin (MBL) oligomers recruit Mannose-Binding Lectin-Associated Serine Protease 2 (MASP-2), which cleaves complement component C4 into the anaphylatoxin C4a and the opsonin C4b in a one-to-one stoichiometric ratio. Consider an in vitro reconstitution in which a defined amount of MASP-2 is added to a surface decorated with high-avidity MBL ligands so that binding and activation are the rate-limiting steps for generating catalytically competent MASP-2. The following experimentally determined parameters are given:\n\n- Turnover number of MASP-2 for C4 cleavage: $k_{\\mathrm{cat}} = 9.5\\ \\mathrm{s}^{-1}$.\n- Michaelis constant for C4: $K_{m} = 1.2\\ \\mu\\mathrm{M}$.\n- Total MASP-2 supplied: $\\left[E\\right]_{\\mathrm{tot}} = 8.0\\ \\mathrm{nM}$.\n- Fraction of MASP-2 stably bound to MBL on the surface: $f_{\\mathrm{bind}} = 0.75$.\n- Conditional activation fraction of the bound MASP-2 (autoactivation upon clustering): $f_{\\mathrm{act}} = 0.80$.\n- Inactivation by C1 esterase inhibitor (C1-INH) under these conditions removes a fraction $f_{\\mathrm{inh}} = 0.10$ of the catalytically active MASP-2.\n- Initial C4 concentration: $\\left[S\\right]_{0} = 1.5\\ \\mu\\mathrm{M}$.\n\nAssume a single-substrate mechanism with the quasi–steady-state approximation, negligible product inhibition at initial times, and that the rate of C4a formation equals the rate of C4b formation and equals the rate of C4 consumption. Using only the standard definitions of turnover number and the Michaelis constant for a single-substrate enzyme under initial-rate conditions, compute the initial rate of C4a (equivalently C4b) generation. Express your final rate in $\\mathrm{nM}\\ \\mathrm{s}^{-1}$ and round your answer to three significant figures.", "solution": "The problem will first be subjected to rigorous validation.\n\n**Step 1: Extract Givens**\n- Turnover number of MASP-2: $k_{\\mathrm{cat}} = 9.5\\ \\mathrm{s}^{-1}$\n- Michaelis constant for C4: $K_{m} = 1.2\\ \\mu\\mathrm{M}$\n- Total MASP-2 supplied: $[E]_{\\mathrm{tot}} = 8.0\\ \\mathrm{nM}$\n- Fraction of MASP-2 bound to MBL: $f_{\\mathrm{bind}} = 0.75$\n- Conditional activation fraction of bound MASP-2: $f_{\\mathrm{act}} = 0.80$\n- Fraction of active MASP-2 removed by C1-INH: $f_{\\mathrm{inh}} = 0.10$\n- Initial C4 concentration: $[S]_{0} = 1.5\\ \\mu\\mathrm{M}$\n- Stoichiometry of C4 cleavage into C4a and C4b is one-to-one.\n- The model to be used is the Michaelis-Menten equation under the quasi–steady-state approximation.\n- Rate of C4a formation equals the rate of C4b formation and equals the rate of C4 consumption.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded, describing a standard biochemical scenario of enzyme kinetics within the known lectin complement pathway. The parameters provided ($k_{\\mathrm{cat}}$, $K_m$, concentrations) are physically and biologically plausible for such a system. The problem is well-posed, providing all necessary data and a clear objective. It is specified using objective, unambiguous language. The problem is self-contained and free of internal contradictions. The request to use the Michaelis-Menten model is appropriate for the described conditions (initial rate, single substrate, negligible product inhibition).\n\n**Step 3: Verdict and Action**\nThe problem is deemed valid. A solution will be provided.\n\nThe objective is to compute the initial rate of C4a generation, which we denote as $v_0$. The problem states that this rate is equivalent to the rate of consumption of the substrate, C4. Under the specified conditions (initial-rate, quasi–steady-state approximation), this rate is described by the Michaelis-Menten equation:\n$$\nv_0 = \\frac{V_{\\max} [S]_0}{K_m + [S]_0}\n$$\nwhere $[S]_0$ is the initial substrate concentration and $V_{\\max}$ is the maximum reaction rate.\n\nThe maximum rate $V_{\\max}$ is defined as:\n$$\nV_{\\max} = k_{\\mathrm{cat}} [E]_{\\mathrm{active}}\n$$\nwhere $k_{\\mathrm{cat}}$ is the turnover number and $[E]_{\\mathrm{active}}$ is the concentration of the catalytically active enzyme, in this case, MASP-2.\n\nIt is necessary to first determine $[E]_{\\mathrm{active}}$ from the total amount of MASP-2 supplied, $[E]_{\\mathrm{tot}}$. The problem provides a sequence of events that reduce the total enzyme concentration to the final active concentration.\n\n1.  The total concentration of MASP-2 is given as $[E]_{\\mathrm{tot}} = 8.0\\ \\mathrm{nM}$.\n\n2.  A fraction $f_{\\mathrm{bind}} = 0.75$ of this total amount binds to the MBL-decorated surface. The concentration of bound MASP-2, $[E]_{\\mathrm{bound}}$, is:\n    $$\n    [E]_{\\mathrm{bound}} = [E]_{\\mathrm{tot}} \\times f_{\\mathrm{bind}}\n    $$\n\n3.  Of this bound population, a fraction $f_{\\mathrm{act}} = 0.80$ becomes activated. The concentration of activated MASP-2 before accounting for inhibition, $[E]_{\\mathrm{act, gross}}$, is:\n    $$\n    [E]_{\\mathrm{act, gross}} = [E]_{\\mathrm{bound}} \\times f_{\\mathrm{act}} = [E]_{\\mathrm{tot}} \\times f_{\\mathrm{bind}} \\times f_{\\mathrm{act}}\n    $$\n\n4.  Finally, a fraction $f_{\\mathrm{inh}} = 0.10$ of the catalytically active MASP-2 is inactivated by C1-INH. This means the fraction that remains active is $(1 - f_{\\mathrm{inh}})$. The final concentration of catalytically competent MASP-2, $[E]_{\\mathrm{active}}$, is therefore:\n    $$\n    [E]_{\\mathrm{active}} = [E]_{\\mathrm{act, gross}} \\times (1 - f_{\\mathrm{inh}}) = [E]_{\\mathrm{tot}} \\times f_{\\mathrm{bind}} \\times f_{\\mathrm{act}} \\times (1 - f_{\\mathrm{inh}})\n    $$\n\nSubstituting the given numerical values:\n$$\n[E]_{\\mathrm{active}} = (8.0\\ \\mathrm{nM}) \\times (0.75) \\times (0.80) \\times (1 - 0.10)\n$$\n$$\n[E]_{\\mathrm{active}} = (8.0\\ \\mathrm{nM}) \\times (0.75) \\times (0.80) \\times (0.90)\n$$\n$$\n[E]_{\\mathrm{active}} = (6.0\\ \\mathrm{nM}) \\times (0.80) \\times (0.90)\n$$\n$$\n[E]_{\\mathrm{active}} = (4.8\\ \\mathrm{nM}) \\times (0.90) = 4.32\\ \\mathrm{nM}\n$$\nThe concentration of active MASP-2 is $4.32\\ \\mathrm{nM}$.\n\nNow, we can calculate $V_{\\max}$ using the given $k_{\\mathrm{cat}} = 9.5\\ \\mathrm{s}^{-1}$:\n$$\nV_{\\max} = k_{\\mathrm{cat}} [E]_{\\mathrm{active}} = (9.5\\ \\mathrm{s}^{-1}) \\times (4.32\\ \\mathrm{nM}) = 41.04\\ \\mathrm{nM}\\ \\mathrm{s}^{-1}\n$$\n\nWith $V_{\\max}$, we can compute the initial rate $v_0$ using the Michaelis-Menten equation. The given values are $[S]_0 = 1.5\\ \\mu\\mathrm{M}$ and $K_m = 1.2\\ \\mu\\mathrm{M}$. The concentration units of $[S]_0$ and $K_m$ are consistent, so they can be used directly. The resulting rate will be in the units of $V_{\\max}$, which is $\\mathrm{nM}\\ \\mathrm{s}^{-1}$ as required.\n$$\nv_0 = \\frac{V_{\\max} [S]_0}{K_m + [S]_0} = \\frac{(41.04\\ \\mathrm{nM}\\ \\mathrm{s}^{-1}) \\times (1.5\\ \\mu\\mathrm{M})}{(1.2\\ \\mu\\mathrm{M}) + (1.5\\ \\mu\\mathrm{M})}\n$$\n$$\nv_0 = \\frac{41.04 \\times 1.5}{2.7}\\ \\mathrm{nM}\\ \\mathrm{s}^{-1}\n$$\n$$\nv_0 = \\frac{61.56}{2.7}\\ \\mathrm{nM}\\ \\mathrm{s}^{-1}\n$$\n$$\nv_0 = 22.8\\ \\mathrm{nM}\\ \\mathrm{s}^{-1}\n$$\nThis is the initial rate of C4 consumption, which is equal to the initial rate of C4a or C4b generation. The result is already expressed to three significant figures, as requested.", "answer": "$$\n\\boxed{22.8}\n$$", "id": "2898645"}, {"introduction": "The entire lectin pathway cascade hinges on the precise proteolytic activity of MASP-2. This thought experiment probes the fundamental mechanism of serine proteases by asking you to predict the consequences of a 'catalytically dead' mutant within a reconstituted system [@problem_id:2898691]. By analyzing the effect of an active-site mutation, you will solidify your understanding of how the function of a single critical residue dictates the fate of the entire downstream pathway, from C4 cleavage to C3 convertase assembly.", "problem": "You are reconstituting the lectin complement pathway on a mannan-coated surface using purified human components. Mannan-binding lectin (MBL) is pre-incubated to bind the surface, and then one of two conditions is applied: either wild-type MASP-2 (MBL-associated serine protease-2) or a MASP-2 variant bearing an active-site mutation $S \\to A$ in the catalytic serine. The system contains purified C4, C2, and C3, physiological $\\mathrm{Ca}^{2+}$ and $\\mathrm{Mg}^{2+}$, and no other proteases (in particular, MASP-1/MASP-3 are absent). Readouts include surface C4b deposition, fluid-phase C2a generation, and surface C3b deposition, each measured after a fixed incubation period. Based only on first principles about serine protease catalysis, zymogen activation, and the assembly of the lectin-pathway C3 convertase, which of the following best describes the outcome when the MASP-2 active-site $S \\to A$ mutant replaces wild-type MASP-2?\n\nA. No detectable C4 or C2 cleavage and no C3b deposition; MBL binding to mannan is preserved but the proteolytic steps fail.\n\nB. Normal C4 cleavage but no C2 cleavage, leading to accumulation of surface C4b without C3b deposition.\n\nC. Partial C4 and C2 cleavage at reduced rates, yielding a low but measurable level of C3b deposition.\n\nD. No change in any readout because MASP-1 functionally compensates for MASP-2 in the reconstituted system.\n\nE. Abolished C4 cleavage, but spontaneous C2 activation suffices to form $C4b2a$ and drive minimal C3b deposition.", "solution": "The problem statement is a valid, well-posed biochemical question grounded in the established principles of enzymology and immunology. It describes a controlled *in vitro* experiment to probe the function of a specific protein, MBL-associated serine protease-2 (MASP-2), within the lectin complement pathway. The conditions are clearly defined, including the composition of the system and the specific mutation introduced. I will proceed with the derivation.\n\nThe fundamental principles governing this system are:\n$1$. The catalytic mechanism of serine proteases.\n$2$. The sequential activation cascade of the lectin complement pathway.\n\n**Principle $1$: Serine Protease Catalysis and the Effect of the $S \\to A$ Mutation**\n\nSerine proteases, such as MASP-2, utilize a catalytic triad in their active site, which classically includes a serine (Ser) residue. The hydroxyl group ($-\\text{OH}$) of this serine acts as a potent nucleophile to attack the peptide bond of the substrate, initiating catalysis. The problem states that this catalytic serine is mutated to an alanine (Ala), a mutation denoted as $S \\to A$. An alanine residue possesses a methyl group ($-\\text{CH}_3$) as its side chain. This group is chemically inert, non-polar, and cannot function as a nucleophile. Therefore, a MASP-2 protein bearing an $S \\to A$ mutation in its active site is catalytically inactive or \"dead\". It can no longer perform its proteolytic function. This is not a mutation that merely reduces activity; it abolishes it entirely.\n\n**Principle $2$: The Lectin Pathway Cascade**\n\nThe sequence of events in the reconstituted system with wild-type MASP-2 would be as follows:\na. Mannan-binding lectin (MBL) binds to the mannan-coated surface.\nb. This binding induces a conformational change in the associated MASP-2 zymogen, activating its protease function.\nc. Active MASP-2 cleaves its first substrate, complement component 4 (C4), into a small fragment C4a and a large fragment C4b.\nd. The nascent C4b fragment contains a reactive internal thioester bond that allows it to covalently attach to the surface near the site of activation. This is measured as \"surface C4b deposition\".\ne. Active MASP-2 also cleaves its second substrate, complement component 2 (C2), into C2a and C2b. This cleavage is most efficient when C2 is bound to surface-deposited C4b. The generation of the C2a fragment is measured as \"fluid-phase C2a generation\".\nf. The C2a fragment associates with surface-bound C4b to form the bimolecular complex $C4b2a$. This complex is the C3 convertase of the lectin pathway.\ng. The $C4b2a$ convertase is an active enzyme (with the proteolytic site residing in the C2a subunit) that cleaves complement component 3 (C3) into C3a and C3b.\nh. The resulting C3b fragment, like C4b, has a reactive thioester and deposits onto the surface. This is \"surface C3b deposition\".\n\n**Analysis of the System with Mutant MASP-2**\n\nNow, we replace the wild-type MASP-2 with the catalytically inactive $S \\to A$ mutant.\n- The initial binding of MBL to the mannan-coated surface is a protein-carbohydrate interaction and is independent of the proteolytic activity of its associated proteases. The problem confirms this is preserved. The inactive MASP-2 remains complexed with MBL.\n- When the cascade should begin (step b), the MASP-2 mutant, despite undergoing conformational changes upon MBL binding, cannot cleave any substrates because its catalytic machinery has been ablated (Principle $1$).\n- Therefore, MASP-2 cannot cleave C4. No C4b is generated, and thus there will be zero surface C4b deposition.\n- Similarly, MASP-2 cannot cleave C2. No C2a is generated, and thus there will be zero fluid-phase C2a generation.\n- Since neither C4b nor C2a is produced, the C3 convertase ($C4b2a$) cannot be assembled.\n- Without the C3 convertase, C3 will not be cleaved. No C3b will be generated, and thus there will be zero surface C3b deposition.\n\nIn summary, the mutation halts the entire proteolytic cascade at its inception. All readouts downstream of MBL binding—C4b deposition, C2a generation, and C3b deposition—will be at baseline, undetectable levels.\n\n**Evaluation of Options:**\n\n**A. No detectable C4 or C2 cleavage and no C3b deposition; MBL binding to mannan is preserved but the proteolytic steps fail.**\nThis statement accurately describes the predicted outcome. The catalytically dead MASP-2 cannot initiate cleavage of C4 or C2. Consequently, no C3 convertase forms, and no C3b is deposited. The initial recognition step of MBL binding is unaffected.\n**Verdict: Correct.**\n\n**B. Normal C4 cleavage but no C2 cleavage, leading to accumulation of surface C4b without C3b deposition.**\nThis is incorrect. The $S \\to A$ mutation ablates the single catalytic site of MASP-2. It is mechanistically impossible for the enzyme to cleave one substrate (C4) but not another (C2) when the tool for cleavage itself has been destroyed. The premise of \"Normal C4 cleavage\" is false.\n**Verdict: Incorrect.**\n\n**C. Partial C4 and C2 cleavage at reduced rates, yielding a low but measurable level of C3b deposition.**\nThis is incorrect. An $S \\to A$ mutation in a catalytic serine is not expected to cause a partial reduction in activity (a hypomorphic phenotype). It is a functional null mutation. The methyl group of alanine cannot substitute for the nucleophilic hydroxyl group of serine in any meaningful way. There is no basis for expecting any cleavage, even at reduced rates.\n**Verdict: Incorrect.**\n\n**D. No change in any readout because MASP-1 functionally compensates for MASP-2 in the reconstituted system.**\nThis is incorrect. The problem statement explicitly and critically states that the system is reconstituted with purified components and that \"MASP-1/MASP-3 are absent\". Therefore, functional compensation by MASP-1 is impossible, as it is not present. This option contradicts the given experimental conditions.\n**Verdict: Incorrect.**\n\n**E. Abolished C4 cleavage, but spontaneous C2 activation suffices to form $C4b2a$ and drive minimal C3b deposition.**\nThis statement is internally contradictory and factually flawed. It correctly posits that C4 cleavage is abolished. However, it then claims the formation of $C4b2a$. The formation of this complex requires C4b as a scaffold. If C4 cleavage is abolished, there is no C4b, and $C4b2a$ cannot form. The idea of \"spontaneous C2 activation\" is also not a significant pathway; C2 activation requires cleavage by a protease, which in this pathway is MASP-2.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2898691"}]}